Stock · ZYDUSLIFE · Healthcare
ZYDUSLIFE share price target 2026
Support, resistance, the F&O structure and the BazaarBaazi Crack Score for ZYDUS LIFESCIENCES LIMITED, refreshed every end-of-day run. A systematic, data-only read on ZYDUS LIFESCIENCES LIMITED: where it trades versus its 50-day and 200-day lines, the live 52-week range, and momentum, refreshed from the scanner's real price series each run.
The verdict
BazaarBaazi reads ZYDUSLIFE as constructive with a Crack Score of 98/100 as of 21 Jul 2026.
BazaarBaaziSource & method
The scanner's readNear-perfect · scanned 21 Jul 2026
Where ZYDUSLIFE stands on the 500-name BazaarBaazi setup scanner: technicals, filed fundamentals and money flow read together, refreshed every run.
One directional side cleared its price-structure, filed-evidence and signed money-flow gates with no blocking red flag.
Technical axis
100/100Fundamental axis
100/100Money flow
64/100Result pulse · Q4 FY26
80/100Named setups in force
- stage2 uptrend
- RS leader
- quality margins
- relative value
- result winner
Technical evidence
price above 50DMA
price above 150DMA
price above 200DMA
50 > 150 > 200 DMA (clean stack)
relative strength rising vs NIFTY
RS line near its highs (leadership)
RS slope +20.7% (3m)
outperforming and above 50DMA
Fundamental evidence
net margin 17.67% (high)
result score 80.0/100
profit not shrinking YoY
revenue +16.22% YoY
cheaper than sector (0.45x median)
bottom-half P/E within sector
result score 80.0/100
earnings not shrinking
result score 80.0/100 (top tier)
strong filed quarter
profit up YoY
revenue up YoY
Valuation and context
P/E 22.8 vs sector median 50.4 (0.45x, 4th pctile)
P/E 1.12x its own ~15m median (20.4)
Relative valuation
P/E (TTM)
22.8P/E vs sector
+0.5%Sector percentile
4PEG
2.92Growth gap
-3.4%P/E vs own history
+1.1%The engine's trade frame
Entry zone
1,143.1Stop
1,095.1Target 1
1,239.1Target 2
1,287.1Risk / reward
4.2% risk · 2.0RScanner levels from the deterministic engine run of 2026-07-21, not a SEBI-registered recommendation and not investment advice. The fundamental axis reads the official filing: Q4 FY26 result.
Price target: support and resistanceComputed 21 Jul 2026
Support and resistance for ZYDUSLIFE are read inside the latest show; no spot was printed in the most recent editorial note.
Levels are read inside the latest show. The most recent editorial reference is Systematic Read on 21 Jul 2026.
These are structural reference lines, not a SEBI-registered price target. BazaarBaazi is independent media; the levels frame how the desk reads the ZYDUSLIFE chart, refreshed every end-of-day run.
The Crack Score, and how it is built98 / 100 · High conviction
The Crack Score is a deterministic 0 to 100 conviction number. Here is exactly what moved it for ZYDUSLIFE, so the figure is a transparent signal rather than a vibe.
Base 50, adjusted by the factors above and clamped to 0 to 100. How the Crack Score works.
The F&O viewHorizon · swing
How the futures and options structure on ZYDUSLIFE reads right now.
The editorial price read on ZYDUSLIFE is bullish. Strike-level option inventory is unavailable, so the page withholds writer, wall and pin claims. Single-stock F&O on ZYDUSLIFE can be thinner than index F&O, so the desk weights price and filed evidence over raw OI. This is not a derivatives trade recommendation.
Why it movedLatest editorial line
The most recent BazaarBaazi read on what is driving ZYDUSLIFE.
Systematic read: a disclosed, data-only model on real 1-year price structure.
Read in Systematic Read on 21 Jul 2026. Why ZYDUSLIFE moved, the living explainer, tracks every move on one URL.
Latest filed resultsQ4 FY26
ZYDUS LIFESCIENCES LIMITED's most recent quarter, parsed straight from the official NSE filing. Every figure links back to its primary source.
Result Pulse
80 / 100Revenue
Rs 7,587 crNet profit
Rs 1,341 crEPS (quarter)
Rs 12.65| Growth | YoY | QoQ |
|---|---|---|
| Revenue | +16.2% | +10.5% |
| Net profit | +7.8% | +31.1% |
| Net margin | +17.7% | |
Figures are the Q4 FY26 result for ZYDUS LIFESCIENCES LIMITED, parsed straight from the official NSE integrated filing and verified to the paisa. The EPS shown is for the quarter, not a trailing-twelve-month figure, so it is not a P/E input.
Earnings history, every filed quarter32 quarters on record
ZYDUS LIFESCIENCES LIMITED's official quarterly revenue, EPS and Result Pulse trail, every quarter the desk holds from the verified filings export, back to 30 Jun 2018. These are quarterly facts, not TTM valuation inputs.
ZYDUSLIFE official result trail
32 quarters
Quarterly figures only: revenue, net profit and EPS are copied from official filings. EPS here is not trailing twelve month EPS and is not used for valuation.
| Quarter | Revenue | EPS | PAT YoY | Pulse | Source |
|---|---|---|---|---|---|
| Q4 FY26ended 31 Mar 2026 / Consolidated, audited | Rs 7,587 cr | Rs 12.65 | n/a | n/a | Filing |
| Q3 FY26ended 31 Dec 2025 / Consolidated, audited | Rs 6,865 cr | Rs 10.36 | n/a | 44/100 | Filing |
| Q2 FY26ended 30 Sep 2025 / Consolidated, audited | Rs 6,123 cr | Rs 12.51 | n/a | n/a | Filing |
| Q1 FY26ended 30 Jun 2025 / Consolidated, audited | Rs 6,574 cr | Rs 14.58 | n/a | n/a | Filing |
| Q4 FY25ended 31 Mar 2025 / Consolidated, audited | Rs 6,528 cr | Rs 11.64 | n/a | n/a | Filing |
| Q3 FY25ended 31 Dec 2024 / Consolidated, audited | Rs 5,269 cr | Rs 10.17 | n/a | n/a | Filing |
| Q2 FY25ended 30 Sep 2024 / Consolidated, audited | Rs 5,237 cr | Rs 9.06 | n/a | n/a | Filing |
| Q1 FY25ended 30 Jun 2024 / Consolidated, audited | Rs 6,208 cr | Rs 14.11 | n/a | n/a | Filing |
| Q4 FY24ended 31 Mar 2024 / Consolidated, audited | Rs 5,534 cr | Rs 11.69 | n/a | n/a | Filing |
| Q3 FY24ended 31 Dec 2023 / Consolidated, audited | Rs 4,505 cr | Rs 7.80 | n/a | n/a | Filing |
| Q2 FY24ended 30 Sep 2023 / Consolidated, audited | Rs 4,369 cr | Rs 7.91 | n/a | n/a | Filing |
| Q1 FY24ended 30 Jun 2023 / Consolidated, audited | Rs 5,140 cr | Rs 10.74 | n/a | n/a | Filing |
| Q4 FY23ended 31 Mar 2023 / Consolidated, audited | Rs 5,011 cr | Rs 2.93 | n/a | n/a | Filing |
| Q3 FY23ended 31 Dec 2022 / Consolidated, audited | Rs 4,362 cr | Rs 6.15 | n/a | n/a | Filing |
| Q2 FY23ended 30 Sep 2022 / Consolidated, audited | Rs 4,135 cr | Rs 5.15 | n/a | n/a | Filing |
| Q1 FY23ended 30 Jun 2022 / Consolidated, audited | Rs 4,073 cr | Rs 5.06 | n/a | n/a | Filing |
| Q4 FY22ended 31 Mar 2022 / Consolidated, audited | Rs 3,864 cr | Rs 3.88 | n/a | n/a | Filing |
| Q3 FY22ended 31 Dec 2021 / Consolidated, audited | Rs 3,655 cr | Rs 4.89 | n/a | n/a | Filing |
| Q2 FY22ended 30 Sep 2021 / Consolidated, audited | Rs 3,785 cr | Rs 29.32 | n/a | n/a | Filing |
| Q1 FY22ended 30 Jun 2021 / Consolidated, audited | Rs 4,025 cr | Rs 5.74 | n/a | n/a | Filing |
| Q4 FY21ended 31 Mar 2021 / Consolidated, audited | Rs 3,847 cr | Rs 6.63 | n/a | n/a | Filing |
| Q3 FY21ended 31 Dec 2020 / Consolidated, audited | Rs 3,796 cr | Rs 5.15 | n/a | n/a | Filing |
| Q2 FY21ended 30 Sep 2020 / Consolidated, audited | Rs 3,820 cr | Rs 4.62 | n/a | n/a | Filing |
| Q1 FY21ended 30 Jun 2020 / Consolidated, audited | Rs 3,640 cr | Rs 4.43 | n/a | n/a | Filing |
| Q4 FY20ended 31 Mar 2020 / Consolidated, audited | Rs 3,752 cr | Rs 3.83 | n/a | n/a | Filing |
| Q3 FY20ended 31 Dec 2019 / Consolidated, audited | Rs 3,638 cr | Rs 3.65 | n/a | n/a | Filing |
| Q2 FY20ended 30 Sep 2019 / Consolidated, audited | Rs 3,367 cr | Rs 1.05 | n/a | n/a | Filing |
| Q1 FY20ended 30 Jun 2019 / Consolidated, audited | Rs 3,496 cr | Rs 2.97 | n/a | n/a | Filing |
| Q4 FY19ended 31 Mar 2019 / Consolidated, audited | Rs 3,733 cr | Rs 4.49 | n/a | n/a | Filing |
| Q3 FY19ended 31 Dec 2018 / Consolidated, audited | Rs 3,578 cr | Rs 4.99 | n/a | n/a | Filing |
| Q2 FY19ended 30 Sep 2018 / Consolidated, audited | Rs 2,961 cr | Rs 4.08 | n/a | n/a | Filing |
| Q1 FY19ended 30 Jun 2018 / Consolidated, audited | Rs 2,894 cr | Rs 4.50 | n/a | n/a | Filing |
The official financialsFiled to 31 Mar 2026
ZYDUS LIFESCIENCES LIMITED's statements as filed: trailing twelve month P&L, the balance sheet, and the cash engine. Parsed from official XBRL, shown in crore.
Trailing twelve months, on filed quarters
Revenue (TTM)
27,148 crNet profit (TTM)
5,124 crEBIT (TTM)
7,060 crProfit before tax (TTM)
6,621 crNet margin (TTM)
18.9%Finance costs (TTM)
439 crBalance sheet, as filed 2026-03-31
Total assets
52,407 crShareholder equity
29,582 crTotal borrowings
11,770 crCash and equivalents
855 crInventory
5,628 crTrade receivables
5,416 crThe cash engine, latest filed year
Operating cash flow
2,117 crCapex
3,394 crFree cash flow
-1,277 crInvesting flow
-8,296 crFinancing flow
5,997 crAnnual trail, filed year over filed year
| Year | Revenue | Net profit | Equity | Borrowings | CFO |
|---|---|---|---|---|---|
| FY26 | 27,148 cr | 5,124 cr | 29,582 cr | 11,770 cr | 2,117 cr |
| FY25 | 23,242 cr | 4,673 cr | 26,358 cr | 3,170 cr | 6,777 cr |
| FY24 | 19,547 cr | 3,973 cr | 22,102 cr | 769 cr | 3,228 cr |
| FY23 | 17,237 cr | 2,092 cr | 19,688 cr | 1,163 cr | 2,689 cr |
| FY22 | 15,265 cr | 4,618 cr | 19,054 cr | 4,196 cr | 2,078 cr |
| FY21 | 15,102 cr | 2,185 cr | 14,930 cr | 3,680 cr | n/a |
Every figure is parsed from ZYDUS LIFESCIENCES LIMITED's official NSE XBRL filings by the BazaarBaazi earnings lab and shown in crore rupees. Display data, not a valuation model input.
Management on record21 earnings calls
Every ZYDUSLIFE earnings call BazaarBaazi has indexed, latest 31 May 2026. Read management in its own words, straight from the filed transcript.
ZYDUS LIFESCIENCES LIMITED earnings calls on record
21 calls since 31 Aug 2021
Show 13 older calls
Each entry links to the transcript PDF the company filed with the exchange. Primary sources, in management's own words.
What changed83 disclosures
Every recent official filing from ZYDUS LIFESCIENCES LIMITED, straight from the exchange feed, with the BazaarBaazi Event Heat on the disclosure flow.
ZYDUS LIFESCIENCES LIMITED has filed 83 official disclosures recently. The most recent is a Disclosure dated 14 Jul 2026.
Event Heat
87 / 100The Exchange has sought clarification from Zydus Lifesciences Limited with respect to recent news item captioned Delhi HC Temporarily Restricts Supply Of Zydus Cancer Drug Ikra In AbbVie Patent Dispute. The response from the Company is attached.
The Exchange has sought clarification from Zydus Lifesciences Limited with respect to recent news item captioned Delhi HC Temporarily Restricts Supply Of Zydus Cancer Drug Ikra In AbbVie Patent Dispute. The response from the Company is awaited.
Certificate under SEBI (Depositories and Participants) Regulations, 2018
a press release dated July 03, 2026, titled "Zydus signs MoU with Apollo Hospitals to expand access to the Shield Multi-Cancer Detection test (MCD) in India
Event Heat is a dated net read of ZYDUS LIFESCIENCES LIMITED's last 90 days of official disclosures, balancing the constructive filings against the ones to watch. It is a signal from what the company has filed, not investment advice. Every line above links to its official exchange filing, and the full market desk is at the disclosures hub.
Key fundamentalsEditorial reference
The anchor data BazaarBaazi references when reading the ZYDUSLIFE chart. Not a substitute for a registered research note.
| Ticker | ZYDUSLIFE |
|---|---|
| Full name | ZYDUS LIFESCIENCES LIMITED |
| Sector | Healthcare |
| Index class | LARGE CAP |
| ISIN | INE010B01027 |
| Market-cap band | ~1.2 lakh cr (indicative) |
| Last referenced level | Inside latest show |
| Last session move | Not referenced this cycle |
| Editorial line in | Systematic Read on 21 Jul 2026 |
| Aliases tracked | ZYDUSLIFE |
Reference chartLevels in show
The daily frame the desk reads on ZYDUSLIFE.
FAQ13 reader questions · AEO-eligible
The line on ZYDUSLIFE, distilled and schema-marked for AI Overview, Perplexity, and reader search.
What is the ZYDUSLIFE share price target for 2026?
BazaarBaazi does not publish a SEBI-registered price target on ZYDUSLIFE. The desk reads structural support and resistance inside each show against the printed spot; the most recent editorial line is Systematic Read on 21 Jul 2026.
What is BazaarBaazi's Crack Score for ZYDUSLIFE?
The BazaarBaazi Crack Score for ZYDUSLIFE is 98 out of 100 as of 21 Jul 2026, a high conviction reading. It is a computed conviction number from the signed stance, how consistent the recent verdicts have been, the quality of the printed structure, and how fresh the review is. It is a transparency signal, not investment advice.
What is the F&O view on ZYDUSLIFE?
Strike-level option inventory for ZYDUSLIFE is unavailable, so BazaarBaazi withholds participant, direction and positioning claims. The editorial chart stance is not substituted for an option-chain observation.
What sector is ZYDUSLIFE in and which peers does BazaarBaazi track?
ZYDUSLIFE sits in Healthcare (large cap), indicative market cap ~1.2 lakh cr (indicative), ISIN INE010B01027. The peers BazaarBaazi reads alongside it are GLAND PHARMA LIMITED, Eris Lifesciences Limited, ACUTAAS CHEMICALS LIMITED. A systematic, data-only read on ZYDUS LIFESCIENCES LIMITED: where it trades versus its 50-day and 200-day lines, the live 52-week range, and momentum, refreshed from the scanner's real price series each run.
How often is the ZYDUSLIFE view updated?
This page is one evergreen URL refreshed in place. The Crack Score and levels re-compute on every BazaarBaazi end-of-day run, and the dated stamp shows the last refresh. The latest signed verdict on ZYDUSLIFE is bullish, published in Systematic Read on 21 Jul 2026.
Is ZYDUSLIFE a qualifying setup on the BazaarBaazi scanner right now?
On the 2026-07-21 run of the 500-name BazaarBaazi setup scanner, ZYDUS LIFESCIENCES LIMITED sits in the Near-perfect tier with a setup score of 91/100 (technical 100, fundamental 100). The scanner is a deterministic engine over real OHLCV and official filings, refreshed nightly, and it is a signal rather than investment advice.
Where can I read ZYDUS LIFESCIENCES LIMITED's earnings call transcripts?
BazaarBaazi indexes 21 ZYDUSLIFE earnings calls going back to 2021-08-31, latest 2026-05-31. Every entry on this page links straight to the transcript PDF the company filed with the exchange, so you read management in the primary source.
What was ZYDUS LIFESCIENCES LIMITED's Q4 FY26 net profit?
ZYDUS LIFESCIENCES LIMITED reported a net profit of Rs 1,341 cr for Q4 FY26 (the quarter ended 31 March 2026). That is +7.8% year on year. The figure is from the company's official NSE filing.
What was ZYDUS LIFESCIENCES LIMITED's Q4 FY26 revenue?
ZYDUS LIFESCIENCES LIMITED reported revenue of Rs 7,587 cr for Q4 FY26. That is +16.2% year on year. The figure is from the company's official NSE filing.
How does BazaarBaazi rate ZYDUS LIFESCIENCES LIMITED's Q4 FY26 result?
BazaarBaazi gives ZYDUS LIFESCIENCES LIMITED's Q4 FY26 result a Result Pulse of 80 out of 100, with a verdict of Margin expansion. The Result Pulse is a BazaarBaazi editorial score for the quality of the filed result, not investment advice.
What has Zydus Lifesciences Ltd announced recently?
Zydus Lifesciences Ltd's two most material recent disclosures are a disclosure dated 14 Jul 2026, "The Exchange has sought clarification from Zydus…", and a board meeting dated 10 Jul 2026, "Notice of Annual General Meeting to be held on August 11,…". Both link to the company's own official filing on the BazaarBaazi stock page.
Has Zydus Lifesciences Ltd declared a dividend recently?
Yes. Zydus Lifesciences Ltd filed a dividend disclosure on 19 May 2026, filed as "Record date for the purpose of Dividend is 24-Jul-2026". Any amount shown is the exchange's own record, linked from the BazaarBaazi stock page. A dividend is a declared payout, not a forecast of future returns.
What did Zydus Lifesciences Ltd's latest board meeting cover?
Zydus Lifesciences Ltd's most recent board-meeting disclosure on record dated 10 Jul 2026 reads "Notice of Annual General Meeting to be held on August 11, 2026". That is the agenda as filed with the exchange, linked from the BazaarBaazi stock page, and BazaarBaazi adds no claim of its own to it.
Related stock views
The names BazaarBaazi reads alongside ZYDUSLIFE, each a living view refreshed every end-of-day run.